AustriaAustria

Successful Finance Round

08.05.2004

Vienna - The Vienna-based biotech company Austrianova has achieved a major success in its latest round of financing. The specialist for gene delivery systems recently raised a total of EUR5.5 million in capital at the beginning of 2004, based on an atypical silent (loss sharing) partnership. This follows EUR4.2 million raised in an earlier financing round in 2003.

AustriaAustria

17.03.2011

Vienna – Apeiron Biologics has entered into an exclusive option with the Cleveland Clinic to license a number of novel compounds that are currently in development there. The drug candidates are designed to fight cancer by...

AustriaAustria

06.02.2011

Vienna – Austrian vaccine specialist Intercell has halted the development of its travellers’ diarrhea vaccine patch after the product failed in a Phase III trial. The company’s management says it will now align its structure to...

Clinical Trial, AustriaAustria

06.02.2011

Vienna – Austrian Nabriva Therapeutics AG has recruited 210 patients for a Phase II study with its antibiotic BC-3781, a substance for treating acute bacterial skin infections. In the study, Nabriva will compare response rates of...

AustriaAustria

02.02.2011

Vienna/Darmstadt – Austrian Apeiron Biologics AG has in-licensed Merck's KgaA’s antibody-interleukin fusion protein hu14.18-IL2 for an undisclosed sum. The drug candidate, that is ready to be tested in Phase III studies, binds to...

AustriaAustria

16.12.2010

Vienna – Austrian Affiris AG has bagged EUR368.000 from the Michael J. Fox Foundation within the Parkinson’s Progression Markers Initiative for completion of preclinical development of its PD01 vaccine against Parkinson’s...

AustriaAustria

04.11.2010

Innsbruck – Cholesterol-lowering drugs widely used to prevent heart disease can also boost anti-cancer effect of interleukine-2 (IL-2) immune therapy. When added to tumour cell cultures treated with IL-2, statins dose-dependently...

Displaying results 11 to 20 out of 116

< Previous 11-20 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/nc/news/messages-archive/archive-austria/browse/1/article/successful-finance-round.html

Print Magazine

Event Video

All videos

Events

All Events

Stock list

All quotes

TOP

  • VITA 344.32 EUR6.67%
  • MORPHOSYS74.44 EUR4.04%
  • STRATEC BIOMEDICAL39.84 EUR3.94%

FLOP

  • CYTOS0.16 CHF-5.88%
  • CO.DON2.75 EUR-3.17%
  • ADDEX3.30 CHF-2.94%

TOP

  • BIOFRONTERA2.90 EUR31.8%
  • VITA 344.32 EUR7.2%
  • BB BIOTECH157.70 EUR6.1%

FLOP

  • PAION2.24 EUR-27.7%
  • CYTOS0.16 CHF-23.8%
  • MAGFORCE5.90 EUR-16.9%

TOP

  • SANTHERA85.50 CHF2288.3%
  • CO.DON2.75 EUR183.5%
  • PAION2.24 EUR143.5%

FLOP

  • CYTOS0.16 CHF-95.9%
  • 4SC0.97 EUR-44.3%
  • THERAMETRICS0.08 CHF-42.9%

No liability assumed, Date: 24.10.2014


Current issue

All issues

Product of the week

Products